AMAL Therapeutics (AMAL) is a biotech company and a distinct unit of the Boehringer Ingelheim group, dedicated to developing unique therapeutic vaccines. Our focus is on overcoming the challenges of effective anti-cancer therapy by stimulating a patient's immune system in a groundbreaking way, creating immunological memory, and targeting a broad range of patients. One of our cutting-edge technologies is KISIMA®, a self-adjuvanting peptide/protein-based immunization platform.

It enables the assembly of a chimeric fusion protein with three crucial elements for generating potent immunity: a proprietary cell-penetrating peptide for antigen delivery, a proprietary TLR-peptide agonist as an adjuvant, and a modulable multi-antigenic cargo that can be tailored for different indications. While we harness the power of KISIMA® to discover and develop therapeutic vaccines for various indications, our ultimate vision is to transform the outlook for cancer patients. Our goal is to offer effective cancer therapies that complement existing standards of care without increasing known toxicities, working in synergy with treatments like chemo- and radiotherapies and immune-checkpoint inhibitors.

Headquartered in Geneva, Switzerland, our state-of-the-art facilities on the University of Geneva campus provide access to cutting-edge platforms and expertise. Join us in our mission to revolutionize cancer treatment